January 28, 2013
In this video, Motley Fool health-care analyst David Williamson looks at the newest hepatitis C partnership, this time between small biotech Idenix and big pharma Johnson & Johnson. The race is on to create a cure using a combination of the next generation of interferon-free drugs, and the companies without all the parts for a viable cocktail are frantically teaming up to gain traction before it is too late. Watch to find out what this newest collaboration means for investors in both companies.
In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. It offers everything from baby powder to biologics, and critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.